• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Cineverse Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Friday's Mid-Day Session

    6/30/23 12:34:37 PM ET
    $AAOI
    $ACCD
    $AHI
    $ALVO
    Semiconductors
    Technology
    Business Services
    Consumer Discretionary
    Get the next $AAOI alert in real time by email

    Gainers

    • Addentax Group Corp. (NASDAQ:ATXG) shares jumped 47.3% to $9.68. Addentax Group is launching automation of artificial intelligence internet operational tools project with top Games-as-a-Service firms.
    • CymaBay Therapeutics, Inc. (NASDAQ:CBAY) surged 40% to $10.97.
    • Cyteir Therapeutics, Inc. (NASDAQ:CYT) shares gained 38% to $2.6487. Cyteir Therapeutics reported discontinuation of CYT-0851 development program and planned liquidation and dissolution.
    • TOP Financial Group Limited (NASDAQ:TOP) shares gained 32.2% to $10.31 after the company reported FY23 financial results.
    • Renalytix Plc (NASDAQ:RNLX) shares jumped 31% to $2.66 after the company received FDA De Novo marketing authorization for its KidneyIntelX.dkd prognostic test.
    • Baudax Bio, Inc. (NASDAQ:BXRX) gained 24% to $0.6450 after the company agreed to acquire TeraImmune in a stock-for-stock transaction.
    • Friedman Industries, Incorporated (NYSE:FRD) rose 19.6% to $11.90 after posting a profit for the fourth quarter.
    • CytomX Therapeutics, Inc. (NASDAQ:CTMX) gained 17.7% to $1.65 after the company announced a $30 million private placement from BVF Partners L.P.
    • Rackspace Technology, Inc. (NASDAQ:RXT) gained 15.8% to $2.27. Rackspace Technology partnered with Google Cloud to offer cutting-edge generative AI services and solutions using the FAIR practice.
    • Applied Optoelectronics, Inc. (NASDAQ:AAOI) gained 15.5% to $6.27.
    • MicroVision, Inc. (NASDAQ:MVIS) climbed 12.8% to $4.40.
    • XPeng Inc. (NYSE:XPEV) gained 12.4% to $13.29 after CLSA upgraded the stock from Buy to Outperform and raised the price target from $10 to $13.1. The company, on Thursday. launched G6 Ultra Smart Coupe SUV in China.
    • Alvotech (NASDAQ:ALVO) rose 12.2% to $7.74. The FDA issued a complete response letter to second application for AVT02, biosimilar candidate for Humira.
    • Digital Turbine, Inc. (NASDAQ:APPS) gained 11.3% to $9.58.
    • Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) climbed 11% to $0.6101. Baird maintained Eiger BioPharmaceuticals with an Outperform and raised the price target from $3 to $5.
    • Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) shares rose 9% to $9.98 after the board announced exploration of strategic alternatives to maximize shareholder value.
    • IMAC Holdings, Inc. (NASDAQ:BACK) rose 8.6% to $0.1195 after declining around 4% on Thursday.
    • Accolade, Inc. (NASDAQ:ACCD) gained 8.4% to $13.71 after the company reported better than expected first-quarter earnings.
    • Carnival Corporation (NYSE:CCL) climbed 7.8% to $18.50 after Jefferies upgraded the stock from Hold to Buy and raised the price target from $9 to $25.
    • Better Choice Company Inc. (NYSE:BTTR) shares gained 6.9% to $0.2310 after declining 6% on Thursday. Better Choice recently announced a $5 million investment from Alphia.

    Losers

    • iMedia Brands, Inc. (NASDAQ:IMBIL) dipped 37% to $0.7686 after dropping over 70% on Thursday.
    • Unicycive Therapeutics, Inc. (NASDAQ:UNCY) fell 23.4% to $1.26 after the company provided an update concerning its marketing application for lanthanum dioxycarbonate for hyperphosphatemia in chronic kidney disease patients on dialysis.
    • Apyx Medical Corporation (NASDAQ:APYX) fell 20.4% to $5.32. Apyx® Medical is expected to report financial results for the second quarter on Thursday, Aug. 10.
    • Evelo Biosciences, Inc. (NASDAQ:EVLO) dropped 19.5% to $2.84. Evelo Biosciences announced a 1-for-20 reverse stock split.
    • Paltalk, Inc. (NASDAQ:PALT) shares dipped 18.8% to $2.29.
    • Cineverse Corp. (NASDAQ:CNVS) fell 17.8% to $1.89 after the company reported weak fourth-quarter sales.
    • Surgalign Holdings, Inc. (NASDAQ:SRGA) dipped 17.6% to $0.2249.
    • Fangdd Network Group Ltd. (NASDAQ:DUO) shares dropped 16.2% to $0.8466 after jumping 31% on Thursday.
    • Kintara Therapeutics, Inc. (NASDAQ:KTRA) dipped 16.2% to $3.53. Kintara Therapeutics secured $2 million National Institutes Of Health SBIR grant to support development of REM-001.
    • Kiromic BioPharma, Inc. (NASDAQ:KRBP) fell 14.1% to $2.74. Kiromic Biopharma recently appointed Brian Hungerford as interim CFO.
    • Advanced Health Intelligence Ltd. (NASDAQ:AHI) dropped 12.5% to $4.34. Advanced Health Intelligence announced implementation of ADS ratio change with effect of 1:4 reverse ADS split.
    • Root, Inc. (NASDAQ:ROOT) fell 12% to $9.87. Root said it is not in receipt of any proposal that is either actionable or in the best interests of shareholders.
    • Foghorn Therapeutics Inc. (NASDAQ:FHTX) declined 11.2% to $7.27.
    • TuSimple Holdings Inc. (NASDAQ:TSP) fell 10.4% to $1.6480.
    • Eos Energy Enterprises, Inc. (NASDAQ:EOSE) dropped 10.3% to $4.42 after B. Riley Securities downgraded the stock from Buy to Neutral.
    • P3 Health Partners Inc. (NASDAQ:PIII) fell 9.5% to $2.96. TD Cowen initiated coverage on P3 Health Partners with a Market Perform rating.
    • Novonix Limited (NASDAQ:NVX) dropped 8.1% to $2.50.
    • Hillstream BioPharma, Inc. (NASDAQ:HILS) declined 7.7% to $0.36.
    • Golden Sun Education Group Limited (NASDAQ:GSUN) shares dropped 7.6% to $1.0350.
    • 1-800-FLOWERS.COM, Inc. (NASDAQ:FLWS) dropped 6.5% to $7.77. 1-800-FLOWERS.COM said CEO Christopher Mccann Will be stepping down for personal health reasons, effective July 3, 2023.
    • Ontrak, Inc. (NASDAQ:OTRK) shares fell 6% to $0.4716 after the company filed for secondary stock offering together with warrants.

     

    Now Read This: Bitcoin Tops $31,000; eCash, Bitcoin Cash Among Top Gainers

    Get the next $AAOI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AAOI
    $ACCD
    $AHI
    $ALVO

    CompanyDatePrice TargetRatingAnalyst
    Carnival Corporation
    $CCL
    3/19/2026$31.00Equal-Weight → Overweight
    Morgan Stanley
    CytomX Therapeutics Inc.
    $CTMX
    3/16/2026$12.00Neutral → Overweight
    Analyst
    Apyx Medical Corporation
    $APYX
    3/11/2026$6.00Neutral → Buy
    BTIG Research
    Eos Energy Enterprises Inc.
    $EOSE
    2/27/2026$20.00Buy → Neutral
    Guggenheim
    Applied Optoelectronics Inc.
    $AAOI
    2/27/2026$55.00Outperform → Market Perform
    Northland Capital
    Applied Optoelectronics Inc.
    $AAOI
    2/27/2026$54.00Sell → Neutral
    B. Riley Securities
    Cineverse Corp.
    $CNVS
    2/19/2026$12.00Speculative Buy → Buy
    The Benchmark Company
    Foghorn Therapeutics Inc.
    $FHTX
    2/17/2026$12.00Buy
    Jefferies
    More analyst ratings

    $AAOI
    $ACCD
    $AHI
    $ALVO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    DISTINGUISHED GUEST SPEAKERS TO JOIN SEABOURN CONVERSATIONS ON 2027 WORLD CRUISE

    World-Class Experts, Explorers, and Cultural Figures to Enrich 145-Day Global Journey Aboard Seabourn Quest SEATTLE, March 19, 2026 /PRNewswire/ -- Seabourn, the leader in luxury cruises and expedition travel, has announced a distinguished lineup of speakers joining its acclaimed Seabourn Conversations program for the 2027 World Cruise aboard Seabourn Quest. The 145–day voyage will feature a curated roster of storytellers, adventurers, and thought leaders, who will share insights and perspectives designed to enrich the journey and deepen guests' connection to the destinations they explore.

    3/19/26 2:47:00 PM ET
    $CCL
    $CUK
    Marine Transportation
    Consumer Discretionary

    Princess Cruises Brings Alaska to Life with New North to Alaska Experiences for 2026

    Four New Immersive Onboard Experiences Debut as Princess Prepares for its Largest Alaska Season EverFORT LAUDERDALE, Fla., March 19, 2026 /PRNewswire/ -- In anticipation of the 2026 Alaska season, Princess Cruises, the highest-rated cruise line in Alaska, is debuting four new North to Alaska experiences alongside returning guest favorites. All eight Princess ships sailing in Alaska this season will feature the new programming: Star Princess, Coral Princess, Royal Princess, Ruby Princess, Grand Princess, Emerald Princess, Discovery Princess, and Island Princess. First introduced

    3/19/26 12:00:00 PM ET
    $CCL
    $CUK
    Marine Transportation
    Consumer Discretionary

    Alvotech Q4 2025 and Full Year 2025 Financial Results

    REYKJAVIK, Iceland, March 18, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ICELAND: ALVO, STOCKHOLM: ALVO SDB)) Financial Highlights  A supplemental long‑form earnings release providing additional operational details and business update for Q4 2025 and the full year is available at: https://investors.alvotech.com/earnings-calendar The supplemental document is provided solely for reference and is not part of this SEC Form 6‑K. The Form 6‑K should not be read together with, or construed as referring to, the supplemental long‑form release. Q4 2025 Highlights Total revenues1 were $173 million, up 13% Year-on-Year (YoY)Adjusted EBITDA1 was $69 million with Gross Margin at 66%AVT05 was

    3/18/26 6:15:00 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AAOI
    $ACCD
    $AHI
    $ALVO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SELARSDI issued to ALVOTECH USA INC

    Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-2) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

    10/21/24 10:44:05 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SELARSDI issued to ALVOTECH USA INC

    Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-1) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

    10/21/24 2:59:28 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SELARSDI issued to ALVOTECH USA INC

    Submission status for ALVOTECH USA INC's drug SELARSDI (SUPPL-3) with active ingredient USTEKINUMAB-AEKN has changed to 'Approval' on 10/18/2024. Application Category: BLA, Application Number: 761343, Application Classification:

    10/21/24 2:59:28 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AAOI
    $ACCD
    $AHI
    $ALVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Carnival upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Carnival from Equal-Weight to Overweight and set a new price target of $31.00

    3/19/26 8:22:53 AM ET
    $CCL
    Marine Transportation
    Consumer Discretionary

    CytomX Therapeutics upgraded by Analyst with a new price target

    Analyst upgraded CytomX Therapeutics from Neutral to Overweight and set a new price target of $12.00

    3/16/26 11:34:14 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Apyx Medical upgraded by BTIG Research with a new price target

    BTIG Research upgraded Apyx Medical from Neutral to Buy and set a new price target of $6.00

    3/11/26 8:28:33 AM ET
    $APYX
    Medical/Dental Instruments
    Health Care

    $AAOI
    $ACCD
    $AHI
    $ALVO
    SEC Filings

    View All

    SEC Form 8-K filed by CytomX Therapeutics Inc.

    8-K - CytomX Therapeutics, Inc. (0001501989) (Filer)

    3/19/26 4:05:37 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IMAC Holdings Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Entry into a Material Definitive Agreement

    8-K - IMAC Holdings, Inc. (0001729944) (Filer)

    3/19/26 4:00:29 PM ET
    $BACK
    Medical Specialities
    Health Care

    SEC Form 6-K filed by Alvotech

    6-K - Alvotech (0001898416) (Filer)

    3/19/26 7:11:30 AM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AAOI
    $ACCD
    $AHI
    $ALVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chu Yu-Waye

    4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

    3/19/26 6:41:25 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Mccarthy Sean A.

    4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

    3/19/26 6:35:34 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Belvin Marcia

    4 - CytomX Therapeutics, Inc. (0001501989) (Issuer)

    3/19/26 6:25:33 PM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAOI
    $ACCD
    $AHI
    $ALVO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President / CEO / Director Taylor Mike J bought $9,000 worth of shares (500 units at $18.00), increasing direct ownership by 0.22% to 223,166 units (SEC Form 4)

    4 - FRIEDMAN INDUSTRIES INC (0000039092) (Issuer)

    3/11/26 12:04:07 PM ET
    $FRD
    Steel/Iron Ore
    Industrials

    Director Urban David bought $100,100 worth of shares (16,250 units at $6.16), increasing direct ownership by 35% to 62,471 units (SEC Form 4)

    4 - Eos Energy Enterprises, Inc. (0001805077) (Issuer)

    3/10/26 8:52:43 AM ET
    $EOSE
    Industrial Machinery/Components
    Miscellaneous

    President / CEO / Director Taylor Mike J bought $7,200 worth of shares (400 units at $18.00), increasing direct ownership by 0.18% to 222,666 units (SEC Form 4)

    4 - FRIEDMAN INDUSTRIES INC (0000039092) (Issuer)

    3/5/26 10:48:54 AM ET
    $FRD
    Steel/Iron Ore
    Industrials

    $AAOI
    $ACCD
    $AHI
    $ALVO
    Leadership Updates

    Live Leadership Updates

    View All

    DISTINGUISHED GUEST SPEAKERS TO JOIN SEABOURN CONVERSATIONS ON 2027 WORLD CRUISE

    World-Class Experts, Explorers, and Cultural Figures to Enrich 145-Day Global Journey Aboard Seabourn Quest SEATTLE, March 19, 2026 /PRNewswire/ -- Seabourn, the leader in luxury cruises and expedition travel, has announced a distinguished lineup of speakers joining its acclaimed Seabourn Conversations program for the 2027 World Cruise aboard Seabourn Quest. The 145–day voyage will feature a curated roster of storytellers, adventurers, and thought leaders, who will share insights and perspectives designed to enrich the journey and deepen guests' connection to the destinations they explore.

    3/19/26 2:47:00 PM ET
    $CCL
    $CUK
    Marine Transportation
    Consumer Discretionary

    Groupon Launches Board-Level Artificial Intelligence Committee and Appoints Amit Shah to Board of Directors

    Technology executive and AI entrepreneur to chair new committee as Company positions marketplace for the era of agentic commerceChicago, Illinois--(Newsfile Corp. - March 10, 2026) - Groupon, Inc. (NASDAQ:GRPN) today announced the appointment of Amit Shah to its Board of Directors, effective March 10, 2026, and the formation of a dedicated Artificial Intelligence Committee of the Board. Shah, a seasoned technology executive and AI entrepreneur, will serve as the Committee's inaugural Chair.With this action, Groupon becomes one of the first publicly traded consumer marketplaces to establish a board-level committee dedicated to artificial intelligence. The formation of the Committee reflects t

    3/10/26 4:15:00 PM ET
    $APRN
    $FLWS
    $GRPN
    Catalog/Specialty Distribution
    Consumer Discretionary
    Other Specialty Stores
    Advertising

    Princess Cruises Announces 2028 World Cruise: 115-Day Global Voyage Visiting 49 Destinations Onboard Coral Princess

    See the World, Unpack Once: 2028 World Cruise Features Maiden Call to Mossel Bay, South Africa and Expanded More Ashore ExperiencesFORT LAUDERDALE, Fla., March 10, 2026 /PRNewswire/ -- Princess Cruises announces its spectacular 2028 World Cruise onboard Coral Princess, a 115-day, globe-spanning journey to 49 destinations across 24 countries and five continents - featuring 39 UNESCO World Heritage Sites, more overnight and late-night stays, and a maiden call to Mossel Bay, South Africa, on sale today. Departing January 3, 2028, roundtrip from Fort Lauderdale, or Los Angeles, the

    3/10/26 2:30:00 PM ET
    $CCL
    $CUK
    Marine Transportation
    Consumer Discretionary

    $AAOI
    $ACCD
    $AHI
    $ALVO
    Financials

    Live finance-specific insights

    View All

    CARNIVAL CORPORATION & PLC TO HOLD CONFERENCE CALL ON FIRST QUARTER EARNINGS

    MIAMI, March 17, 2026 /PRNewswire/ -- Carnival Corporation & plc ((NYSE/LSE: CCL, NYSE:CUK) has scheduled a conference call with analysts for Friday, March 27, 2026, at 10 a.m. (EDT); 2 p.m. (GMT) to discuss the company's first quarter financial results which are expected to be released that morning. A simulcast of the call will be available via the company's websites at www.carnivalcorp.com and www.carnivalplc.com.About Carnival Corporation & plc Carnival Corporation & plc is the largest global cruise company, and among the largest leisure travel companies, with a portfolio of world-class cruise lines – AIDA Cruises, Carnival Cruise Line, Costa Cruises, Cunard, Holland America Line, P&O Cru

    3/17/26 9:15:00 AM ET
    $CCL
    $CUK
    Marine Transportation
    Consumer Discretionary

    CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update

    - Announced Positive Data from Phase 1 Dose Expansion Study of varsetatug masetecan ("Varseta-M") EpCAM PROBODY® ADC in Patients with Advanced Colorectal Cancer (CRC) - - FDA interactions targeted for mid-year with goal to align on potential Varseta-M registrational trial design in late line CRC - - Varseta-M Phase 1 study evaluating combination with bevacizumab initiated; Phase 1b/2 chemotherapy combination study to be initiated by the end of 2026 - - Initial CX-801 PROBODY Interferon-alpha-2b Phase 1 combination data with KEYTRUDA® (pembrolizumab) in melanoma expected by the end of 2026 - - Company to host conference call today at 8 a.m. ET / 5 a.m. PT - SOUTH SAN FRANCISCO, Calif., M

    3/16/26 7:05:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CytomX's Varsetatug Masetecan (EpCAM PROBODY® ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer

    - Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W - - Estimated progression free survival of 7.1 months at 10 mg/kg and 6.8 months at 8.6 mg/kg - - Grade 3 diarrhea rate of 10% in ongoing dose optimization cohorts - - FDA interactions targeted for mid-year with goal to align on potential registrational trial design in late-line colorectal cancer (CRC) - - Phase 1 study evaluating combination with bevacizumab initiated; Phase 1b/2 chemotherapy combination study to be initiated by the end of 2026 - - Conference call on Monday, March 16 at 8:00 a.m. ET - SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics

    3/16/26 7:00:00 AM ET
    $CTMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AAOI
    $ACCD
    $AHI
    $ALVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Eos Energy Enterprises Inc.

    SC 13D/A - Eos Energy Enterprises, Inc. (0001805077) (Subject)

    12/17/24 2:48:02 PM ET
    $EOSE
    Industrial Machinery/Components
    Miscellaneous

    SEC Form SC 13G filed by Fangdd Network Group Ltd.

    SC 13G - Fangdd Network Group Ltd. (0001750593) (Subject)

    12/16/24 4:26:40 PM ET
    $DUO
    Real Estate
    Finance

    Amendment: SEC Form SC 13G/A filed by Fangdd Network Group Ltd.

    SC 13G/A - Fangdd Network Group Ltd. (0001750593) (Subject)

    12/16/24 4:24:27 PM ET
    $DUO
    Real Estate
    Finance